Stay updated on Pembrolizumab & Epacadostat in Thymic Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Epacadostat in Thymic Carcinoma Clinical Trial page.

Latest updates to the Pembrolizumab & Epacadostat in Thymic Carcinoma Clinical Trial page
- Check5 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.9%
- Check12 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check19 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check26 days agoChange DetectedThe web page has been updated to announce the modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference1%
- Check55 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check70 days agoChange DetectedThe webpage has undergone significant updates, including the addition of new collaborators and a revision number, while key details about the clinical trial for thymic carcinoma have been removed, including specific study protocols and inclusion/exclusion criteria.SummaryDifference47%
Stay in the know with updates to Pembrolizumab & Epacadostat in Thymic Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Epacadostat in Thymic Carcinoma Clinical Trial page.